Anticoagulation for atrial fibrillation

Cardiology Clinics

Volumn 22, Issue 1, 2004, Pages 47-62

  Fang, Margaret C ^a   Singer, Daniel E ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN ANTICOAGULANT; FLUINDIONE; INDOBUFEN; PHENPROCOUMON; PROSTAGLANDIN SYNTHASE INHIBITOR; TRIFLUSAL; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CARDIOVERSION; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE ASSOCIATION; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LUNG EMBOLISM; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINUS RHYTHM; STROKE; THERAPY; THROMBOCYTE;

EID: 1642422926     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(03)00115-2     Document Type: Review

References (89)

1. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 147:1987;1561-1564.
2. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 22:1991;983-988.
3. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA. 285:2001;2370-2375.
4. Camm A.J., Obel O.A. Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol. 78:1996;3-11.
5. Bogousslavsky J., Van Melle G., Regli F., Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 40:1990;1046-1050.
6. Petersen P., Boysen G., Godtfredsen J., Andersen E., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet. 1:1989;175-178.
7. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 323:1990;1505-1511.
8. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation. 84:1991;527-539.
9. Connolly S., Laupacis A., Gent M., Roberts R., Cairns J., Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 18:1991;349-355.
10. Ezekowitz M., Bridgers S., James K., Carliner N., Colling C., Gornick C., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 327:1992;1406-1412.
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 154:1994;1449-1457.
12. Hull R., Hirsh J., Jay R., Carter C., England C., Gent M., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med. 307:1982;1676-1681.
13. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 333:1995;5-10.
14. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 348:1996;633-638.
15. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet. 343:1994;687-691.
16. Gullov A., Keofoed B., Petersen P., Pedersen T., Andersen E., Godtfredsen J., et al. Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 158:1998;1513-1521.
17. Pengo V., Zasso A., Barbero F., Banzato A., Nante G., Parissenti L., et al. Effectiveness of fixed mini-dose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 82:1998;433-437.
18. Hellemons B., Langenberg M., Lodder J., Vermeer F., Schouten H., Lemmens T., et al. Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 3:1999;958-964.
19. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multi-center, prospective, randomized trial. Stroke. 31:2000;817-821.
20. Lechat P., Lardoux H., Mallet A., Sanchez P., Derumeaux G., Lecompte T., et al. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation: a randomized trial (fluindione, fibrillation auriculaire, aspirin et contraste spontane). Cerebrovasc Dis. 12:2001;245-252.
21. Perez Gomez F. Sr, Zumalde J. Sr, Orriach D., Iriarte J.A., Berjon J., Alegria E., et al. The role of combined antiplatelet plus moderate level of anticoagulation for prevention of embolism in atrial fibrillation. A national randomized, multi-center trial. Circulation. 106:(19):2002;S633.
22. EAFT. (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 342:1993;1255-1262.
23. Hart R., Benavente O., McBride R., Pearce L. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 131:1999;492-501.
24. Segal J., McNamara R., Miller M., Kim N., Goodman S., Powe N., et al. Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med. 15:2000;56-67.
25. Morocutti C., Amabile G., Fattapposta F., Nicolosi A., Matteoli S., Trappolini M., et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) investigators. Stroke. 28:1997;1015-1021.
26. van Walraven C., Hart R.G., Singer D.E., Laupacis A., Connolly S., Petersen P., et al. Oral anticoagulants versus aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 288:2002;2441-2448.
27. Hylek E.M., Go A.S., Chang Y., Jensvold N.G., Henault L.E., Selby J.V., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 349:(11):2003;1019-1026.
28. ACC/AHA/ESC. Guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol. 38:2001;1231-1266.
29. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 347:2002;969-974.
30. van Es R., Jonker J., Verheugt F., Deckers J., Grobbee D. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 360:2002;109-113.
31. Hart R., Pearce L., McBride R., Rothbart R., Asinger R. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 30:1999;1223-1229.
32. Albers G.W., Dalen J.E., Laupacis A., Manning W.J., Petersen P., Singer D.E. Antithrombotic therapy in atrial fibrillation. Chest. 119:2001;194S-206S.
33. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. Arch Intern Med. 158:1998;1316-1320.
34. Hart R., Pearce L., Rothbart R., McAnulty J., Asinger R., Halperin J. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 35:2000;183-187.
35. Pearce L., Hart R., Halperin J. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 109:2000;45-51.
36. Go A., Hylek E., Phillips K.A., Borowsky L., Henault L.E., Chang Y., et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 102:2000;11-13.
37. Stollberger C., Chnupa P., Kronik G., Brainin M., Finsterer J., Schneider B., et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med. 128:1998;630-638.
38. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med. 128:1998;639-647.
39. Loebstein R., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther. 70:2001;159-164.
40. Higashi M., Veenstra D., Kondo L., Wittkowsky A., Srinouanprachanh S., Farin F., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 287:2002;1690-1698.
41. Leung D.Y., Grimm R.A., Klein A.L. Transesophageal echocardiography- guided approach to cardioversion of atrial fibrillation. Prog Cardiovasc Dis. 39:1996;21-32.
42. Landefeld C., Rosenblatt M., Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 87:1989;153-159.
43. Gorter J. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology. 53:1999;1319-1327.
44. van der Meer F., Rosendaal F., Vandenbroucke J., Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med. 1993:1993;1557-1562.
45. Fihn S., McDonell M., Martin D., Henikoff J., Vermes D., Kent D., et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med. 118:1993;511-520.
46. Hylek E., Singer D. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 120:1994;897-902.
47. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 156:1996;409-416.
48. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 348:1996;423-428.
49. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 42:1997;857-865.
50. Wintzen A.R., de Jonge H., Loeliger E.A., Bots G.T. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol. 16:1984;553-558.
51. Berwaerts J., Webster J. Analysis of risk factors involved in oral-anticoagulant-related intracranial hemorrhages. QJM. 93:2000;513-521.
52. Rosand J., Hylek E.M., O'Donnell H.C., Greenberg S.M. Warfarin-associated hemorrhage and cerebral amyloid angiopathy. Neurology. 55:2000;947-957.
53. Smith E.E., Rosand J., Knudsen K.A., Hylek E.M., Greenberg S.M. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 59:2002;193-197.
54. Bungard T.J., Ghali W.A., Teo K.K., McAlister F.A., Tsuyuki R.T. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 160:2000;41-46.
55. Hylek E., Skates S., Sheehan M., Singer D. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 335:1996;540-546.
56. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Developed in collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 38:2001;1231-1266.
57. Go AS, Hylek EM, Phillips KA, Chang, Henault LE, Capra AM, et al. Effectiveness and safety of anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trial results translate into clinical practice? The ATRIA study. JAMA, in press.
58. Fang MC, Stafford R, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med, in press.
59. Stafford R., Radley D.C. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 41:2003;56-61.
60. Chiquette E., Amato M., Bussey H. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med. 158:1998;1641-1647.
61. Fitzmaurice D., Hobbs R., Murray E., Holder R., Allan T., Rose P. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing. Arch Intern Med. 160:2000;2343-2348.
62. Matchar D.B., Samsa G.P., Cohen S.J., Oddone E.Z., Jurgelski A.E. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 113:2002;42-51.
63. Cromheecke M.E., Levi M., Colly L.P., de Mol B.J.M., Prins M.H., Hutten B.A., et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet. 356:2000;97-102.
64. Gustafsson C., Asplund K., Britton M., Norrving B., Olsson B., Marke L.A. Cost-effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 305:1992;1457-1460.
65. Gage B.F., Cardinalli A.B., Albers G.W., Owens D.K. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 274:1995;1839-1845.
66. Lightowlers S., McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke. 29:1998;1827-1832.
67. Solomon N.A., Glick H.A., Russo C.J., Lee J., Schulman K.A. Patient preferences for stroke outcomes. Stroke. 25:1994;1721-1725.
68. Man-Son-Hing M., Laupacis A.A.O.C., Wells G., Lemelin J., Wood W., Dermer M. Warfarin for atrial fibrillation. The patient's perspective. Arch Intern Med. 156:1996;1841-1848.
69. Devereaux P.J., Anderson D.R., Gardner M.J., Putnam W., Flowerdew G.J., Brownell B.F., et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 323:2001;1-7.
70. Gage B.F., Cardinalli A.B., Owens D.K. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 156:1996;1829-1836.
71. Man-Son-Hing M., Laupacis A., O'Connor A.M., Biggs J., Drake E., Yetisir E., et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA. 282:1999;737-743.
72. Leung D.Y., Davidson P.M., Cranney G.B., Walsh W.F. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol. 79:1997;626-629.
73. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 347:2002;1825-1833.
74. Van Gelder I.C., Hagens V.E., Bosker H.A., Kingma J.H., Kamp O., Kingma T., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 347:2002;1834-1840.
75. Haissaguerre M., Jais P., Shah D.C., Takahashi A., Hocini M., Quiniou G., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 339:1998;659-666.
76. Cox J.L., Ad N., Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg. 118:1999;833-840.
77. Resnekov L., McDonald L. Complication in 220 patients with cardiac dysrhythmias treated by phased DC shock and indications for electroconversion. Br Heart J. 29:1967;926-936.
78. Berger M., Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 82:1998;1545-1547.
79. Bjerkelund C., Orning O. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol. 23:1969;208-216.
80. Klein A.L., Grimm R.A., Murray R.D., Apperson-Hansen C., Asinger R., Black I.W., et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 344:2001;1411-1420.
81. Seidl K., Hauer B., Schwick N., Zellner D., Zahn R., Senges J. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol. 82:1998;580-583.
82. Lanzarotti C.J., Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol. 30:1997;1506-1511.
83. Corrado G., Sgalambro A., Mantero A., Gentile F., Gasparini M., Bufalino R., et al. Thromboembolic risk in atrial flutter. The FLASIEC (Flutter Atriale Societa Italiana di Ecografia Cardiovascolare) multi-centre study. Eur Heart J. 22:2001;1042-1051.
84. Heit J., Colwell C., Francis C., Ginsberg J., Berkowitz S., Whipple J., et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med. 161:2001;2215-2221.
85. SPORTIF III Investigators. SPORTIF III: a long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In: American College of Cardiology Scientific Session. Chicago; 2003.
86. Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 61:1996;755-759.
87. Sievert H., Lesh M., Trepels T., Omran H., Bartorelli A., Della Bella P., et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 105:2002;1887-1889.
88. Breslow N., Day N. The design and analysis of cohort studies. Davis W. Statistical methods in cancer research. Volume II:1989;Oxford University Press, New York.
89. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med. 157:1997;1237-1240.